Skip to content

The Impact of Zinc Supplementation on the change in Albuminuria in patients with Diabetic Kidney Disease : A double-blind, placebo-controlled, randomized trial

The Impact of Zinc Supplementation on the change in Albuminuria in patients with Diabetic Kidney Disease : A double-blind, placebo-controlled, randomized trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20250311008
Enrollment
40
Registered
2025-03-11
Start date
2025-04-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic kidney disease DM, DKD, Albuminuria, zinc, ESRD, CKD,Chronic kidney disease

Interventions

Zinc 30 mg per day,Placebo
Placebo Comparator Drug,Placebo Comparator Drug

Sponsors

Department of Medicine Faculty of Medicine Vajira Hospital Navamindradhiraj University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients with chronic kidney disease (CKD) due to type 2 diabetes in a nephrology clinic who have been diagnosed with diabetic kidney disease by a nephrologist 2. have a UACR at least 30 mg/g, confirmed by at least two separate tests conducted at least three months apart, with the most recent UACR test within the past three months 3. Patients with CKD stages 1-5 according to the KDIGO guidelines, with stage 5 patients not receiving renal replacement therapy 4. If patients are receiving Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin Receptor Blockers (ARBs), Mineralocorticoid Receptor Antagonists (MRAs), or SGLT2 inhibitors, their medication doses must have remained unchanged for the past three months 5. Diabetic patients with an HbA1c level of 6.5-8.0

Exclusion criteria

Exclusion criteria: 1. Pregnant or planning to become pregnant, screened using a urine pregnancy test 2. Patients undergoing renal replacement therapy or kidney transplantation 3. Presence of heart failure based on physical examination 4. Urinary tract infection 5. Abnormal AST or ALT levels 6. History of taking any supplements or vitamins within the past three months before enrolling in the study 7. History of non-adherence to treatment or irregular follow-up visits 8. History of adverse reactions to zinc supplementation

Design outcomes

Primary

MeasureTime frame
Albuminuria 6 months Urine albumin creatinine ratio

Secondary

MeasureTime frame
Kidney function 6 months eGFR

Countries

Thailand

Contacts

Public ContactNapassorn Lekwichittada

Department of Medicine Faculty of Medicine Vajira Hospital Navamindradhiraj University

toeids7@gmail.com022444000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026